Fusion Protein Development

Partner with Abzena to accelerate fusion protein development through integrated expertise that reduces risk, enhances developability and manufacturability, and helps deliver innovative therapies to patients faster.

The development and production of biotherapeutic fusion proteins is complex. The development of fusion proteins requires careful consideration of both biological function and manufacturability. Molecular architecture, domain orientation, linker design, stability, aggregation propensity, expression performance, and product quality attributes can all influence a candidate’s path to the clinic. At Abzena, we offer the design and engineering of fusion proteins for a wide range of therapeutic applications. We combine deep scientific expertise in complex biologics through protein engineering, developability, cell line development, and manufacturing to accelerate candidate selection, reduce development risk, and improve the likelihood of clinical success.

Difficult-to-express fusion proteins are an increasingly important class of complex biologics, combining multiple functional domains within a single therapeutic molecule to achieve mechanisms of action that may not be possible with conventional monoclonal antibodies. By bringing together antibodies, receptor domains, cytokines, enzymes, peptides, or other protein components, fusion proteins can be engineered to enhance target engagement, extend half-life, improve pharmacokinetics, and deliver differentiated therapeutic activity.

From Fc-fusion proteins and immunocytokines to receptor fusion proteins and multifunctional protein therapeutics, these modalities are expanding opportunities across oncology, immunology, rare diseases, and other areas of high unmet medical need. As biopharmaceuticals shift toward more complex biologic formats, fusion proteins offer exciting potential for next-generation therapeutic innovation.

Abzena’s integrated expertise helps identify and address these challenges early, enabling the selection and progression of robust fusion protein candidates with greater confidence.

Contact Us

Fusion Protein Design & Development Approach

Successful fusion protein development begins with thoughtful design choices. Decisions made during discovery and lead optimization can significantly impact biological activity, stability, manufacturability, and long-term clinical success.

Abzena’s fusion protein approach includes:

  • Evaluating multiple molecular architectures early in development
  • Exploring domain orientation and linker design to optimize functionality
  • Balancing biological activity with manufacturability requirements
  • Assessing stability and aggregation propensity at the earliest stages
  • Incorporates developability screening alongside functional testing
  • Considers expression performance and scalability from the outset
  • Identifying potential immunogenicity and sequence liabilities before advancement

By evaluating multiple designs in parallel, we can quickly identify optimal candidates while reducing your downstream development risk. This approach ensures that the most promising molecules are selected – not only for biological performance, but also for their ability to be manufactured consistently and efficiently at scale.

Case Study: Self-Assembling Nanoparticle Fusion Protein

Abzena has successfully developed stable, high-expressing cell lines for complex fusion protein modalities, including self-assembling nanoparticle fusion proteins, delivering robust productivity, product quality, and scalability.

In this case study that is available for download, learn how Abzena’s end-to-end expertise and fully integrated cell line development (CLD), process optimization, and scale-up capabilities played a key role in a collaboration with a non-profit research institute working on novel biomedical interventions.

Discover Our Case Study

Integrated Fusion Protein Development from Discovery to GMP

Integrated Bioconjugate & ADC Development Services - Abzena

Fusion proteins often require coordinated expertise across multiple disciplines. Fragmented development strategies can introduce delays, transfer risks, and unnecessary complexity.

Abzena provides stage-appropriate integrated solutions supporting:

  • Discovery & Protein Engineering: Molecular design, format optimization, functional characterization, and developability assessment
  • Cell Line Development: Stable cell line generation, clone selection, and productivity optimization
  • Formulation Development: Optimize stability, and enhance product quality
  • Process Development: Upstream process development, downstream purification strategy, and scale-up readiness
  • Analytical Development: Product characterization, and stability testing
  • GMP Manufacturing: Clinical production, regulatory support, and CMC readiness

By bringing these capabilities together under one organization, and through integrated development solutions we help accelerate timelines from DNA-to-IND while reducing development risk.

Discover Integrated Solutions

Fusion Protein Design & Engineering

Fusion proteins take many forms, each with distinct advantages and development considerations. Each format presents unique challenges related to expression, folding, stability, solubility, and biological activity. Whether your program already has a preferred molecular design or requires format evaluation, Abzena’s protein engineering experts can support the optimization of:

  • Domain architecture
  • Linker selection and engineering
  • Half-life extension strategies
  • Affinity and potency enhancement
  • Sequence optimization
  • Deimmunization and immunogenicity risk reduction
  • Manufacturability improvements
  • Stability enhancement

Our integrated protein engineering and analytical capabilities help identify and address potential liabilities early, increasing confidence as programs progress toward the clinic.

Developing Fusion Proteins with Clinical Success in Mind

Many fusion proteins are inherently more difficult to express than traditional monoclonal antibodies. Complex domain combinations can introduce challenges such as, low expression titers, protein misfolding, stability concerns, and purification complexity. These issues can become significant barriers during cell line development and scale-up if not addressed early.

Abzena’s development philosophy focuses on integrating manufacturability into candidate design from the beginning. Through developability assessments, analytical characterization, and expression screening, we identify risks before they impact timelines or increase development costs. This enables you to make informed decisions and take programs forward with the greatest probability of technical and clinical success.

Contact Us

GMP-Ready Cell Line Development for Fusion Proteins

Cell Line Development Services - Abzena

Efficient production remains one of the most critical factors in successful fusion protein development. Abzena’s GMP-ready AbZelectPRO™ mammalian cell line development platform has been specifically designed to support both conventional biologics and difficult-to-express molecules, including fusion proteins and other complex therapeutic formats. AbZelectPRO™ combines optimized vectors, advanced host cell lines, and streamlined development processes to achieve:

  • Stable pools in as little as three weeks
  • Research cell banks in as little as ten weeks
  • High and stable expression levels
  • Improved scalability
  • Reduced development timelines
  • Enhanced process robustness

Our scientific experts work closely across discovery, protein engineering, analytical development, process development, and manufacturing to ensure a seamless path from candidate selection to GMP production.

Discover AbZelectPRO™

What sets our fusion protein development service apart?

Abzena combines more than two decades of protein engineering, biologics development, and manufacturing expertise to support increasingly complex therapeutic modalities. Our teams have experience developing monoclonal antibodies, bispecifics, multispecifics, fusion proteins, bioconjugates including ADCS and AOCs, and other next-generation biologics.

Abzena offer:

  • Deep expertise in complex biologic modalities
  • Integrated discovery-to-GMP development capabilities
  • Proven protein engineering and developability experience
  • GMP-ready cell line development platforms optimized for difficult-to-express modalities
  • Strong analytical and characterization capabilities
  • Early detection of formulation development risks
  • Focus on manufacturability from the earliest stages
  • Flexible partnership models tailored to program needs
Contact Us

Related Services

Antibody Design & Protein Engineering

Our experts combine antibody design, protein engineering and analytics expertise to design drug candidates, from antibodies, Fab fragments, and fusion proteins, with minimal liabilities and ...

Learn More

Mammalian Cell Line Development

Achieve stable pools in 3 weeks, accelerate from DNA to RCB in just 10 weeks and GMP in 6 months with our industry-leading mammalian cell line development services.

Learn More

Move forward from DNA to IND/CTA faster

Accelerate promising biologic candidates into clinical-ready therapies through integrated DNA-to-IND/CTA programs that reduce risk, shorten timelines, and help bring medicines to patients faster.

Learn More

Fusion Protein FAQs

What is a fusion protein?

A fusion protein is a therapeutic molecule that combines two or more functional protein domains, such as antibodies, receptor domains, cytokines, enzymes, or peptides, into a single construct to deliver enhanced biological activity and therapeutic functionality.

What are Fc-fusion proteins?

Fc-fusion proteins are therapeutic molecules that combine a biologically active protein domain with an antibody Fc region to enhance half-life, stability, and pharmacokinetic performance.

What are the advantages of fusion proteins over monoclonal antibodies?

Fusion proteins can offer advantages over traditional monoclonal antibodies (mAbs) by combining multiple biological functions in a single molecule, enabling enhanced activity, improved pharmacokinetics, extended half-life, and novel mechanisms of action.

How are fusion proteins generated?

Fusion proteins are generated through the joining of two or more different genes, resulting in their combined transcription and translation to produce a single protein.

How are fusion proteins designed?

Fusion proteins are designed by optimizing molecular architecture, domain orientation, linker selection, and functional activity while considering stability, developability, and manufacturability.

What are the main challenges of fusion protein development?

Fusion protein development can be challenged by issues such as low expression, aggregation, stability concerns, product heterogeneity, and complex manufacturing requirements.

Why are fusion proteins difficult to express?

Fusion proteins can be difficult to express because their complex structures may affect protein folding, assembly, stability, and cellular productivity.

How do you improve fusion protein manufacturability?

Fusion protein manufacturability can be improved through early developability assessment, sequence and format optimization, expression screening, and careful evaluation of stability and product quality attributes.

How are fusion proteins manufactured?

Fusion proteins are typically manufactured using engineered mammalian cell lines followed by upstream production, downstream purification, analytical characterization, and GMP manufacturing processes.

How do you develop a stable cell line for fusion proteins?

A stable cell line for fusion proteins is developed by generating and screening high-performing clones that deliver consistent expression, product quality, stability, and scalability throughout development.

What analytical testing is required for fusion proteins?

Fusion protein analytical characterization commonly includes assessments of identity, purity, aggregation, stability, product quality attributes, and overall molecular integrity.

Start Your Fusion Protein Development Program

Partner with Abzena to design, engineer, develop, and manufacture fusion proteins with confidence, from concept through clinical readiness.

Contact Us